PT4028017T - Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes - Google Patents
Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunesInfo
- Publication number
- PT4028017T PT4028017T PT207888686T PT20788868T PT4028017T PT 4028017 T PT4028017 T PT 4028017T PT 207888686 T PT207888686 T PT 207888686T PT 20788868 T PT20788868 T PT 20788868T PT 4028017 T PT4028017 T PT 4028017T
- Authority
- PT
- Portugal
- Prior art keywords
- nuak1
- lrrk2
- dihydrobenzo
- pyrazolo
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- ORQJPWRNWPJVTJ-UHFFFAOYSA-N N1N=CC2=C1C1=C(N=CN2)C=CC=C1 Chemical class N1N=CC2=C1C1=C(N=CN2)C=CC=C1 ORQJPWRNWPJVTJ-UHFFFAOYSA-N 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899908P | 2019-09-13 | 2019-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4028017T true PT4028017T (pt) | 2024-01-16 |
Family
ID=72801756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207888686T PT4028017T (pt) | 2019-09-13 | 2020-09-11 | Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220380374A1 (pt) |
| EP (2) | EP4028017B1 (pt) |
| JP (1) | JP2022548246A (pt) |
| KR (1) | KR20220062038A (pt) |
| CN (1) | CN114793435A (pt) |
| AU (1) | AU2020344216A1 (pt) |
| CA (1) | CA3154123A1 (pt) |
| DK (1) | DK4028017T3 (pt) |
| ES (1) | ES2969088T3 (pt) |
| FI (1) | FI4028017T3 (pt) |
| IL (1) | IL291335A (pt) |
| PL (1) | PL4028017T3 (pt) |
| PT (1) | PT4028017T (pt) |
| RS (1) | RS65045B1 (pt) |
| SI (1) | SI4028017T1 (pt) |
| WO (1) | WO2021048620A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022378463A1 (en) | 2021-10-25 | 2024-05-09 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034193B1 (ru) * | 2011-04-21 | 2020-01-15 | Оригенис Гмбх | Гетероциклические соединения в качестве ингибиторов киназ |
-
2020
- 2020-09-11 CN CN202080078998.0A patent/CN114793435A/zh active Pending
- 2020-09-11 KR KR1020227011532A patent/KR20220062038A/ko unknown
- 2020-09-11 CA CA3154123A patent/CA3154123A1/en active Pending
- 2020-09-11 SI SI202030353T patent/SI4028017T1/sl unknown
- 2020-09-11 FI FIEP20788868.6T patent/FI4028017T3/fi active
- 2020-09-11 JP JP2022516097A patent/JP2022548246A/ja active Pending
- 2020-09-11 AU AU2020344216A patent/AU2020344216A1/en active Pending
- 2020-09-11 ES ES20788868T patent/ES2969088T3/es active Active
- 2020-09-11 WO PCT/IB2020/000730 patent/WO2021048620A1/en active Application Filing
- 2020-09-11 US US17/642,142 patent/US20220380374A1/en active Pending
- 2020-09-11 PT PT207888686T patent/PT4028017T/pt unknown
- 2020-09-11 DK DK20788868.6T patent/DK4028017T3/da active
- 2020-09-11 PL PL20788868.6T patent/PL4028017T3/pl unknown
- 2020-09-11 RS RS20240045A patent/RS65045B1/sr unknown
- 2020-09-11 EP EP20788868.6A patent/EP4028017B1/en active Active
- 2020-09-11 EP EP23205855.2A patent/EP4327884A3/en active Pending
-
2022
- 2022-03-13 IL IL291335A patent/IL291335A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3154123A1 (en) | 2021-03-18 |
| AU2020344216A1 (en) | 2022-03-31 |
| RS65045B1 (sr) | 2024-02-29 |
| WO2021048620A1 (en) | 2021-03-18 |
| DK4028017T3 (da) | 2024-01-15 |
| KR20220062038A (ko) | 2022-05-13 |
| IL291335A (en) | 2022-05-01 |
| FI4028017T3 (fi) | 2024-01-11 |
| US20220380374A1 (en) | 2022-12-01 |
| EP4028017A1 (en) | 2022-07-20 |
| EP4327884A3 (en) | 2024-05-01 |
| EP4327884A2 (en) | 2024-02-28 |
| SI4028017T1 (sl) | 2024-04-30 |
| EP4028017B1 (en) | 2023-12-06 |
| JP2022548246A (ja) | 2022-11-17 |
| ES2969088T3 (es) | 2024-05-16 |
| CN114793435A (zh) | 2022-07-26 |
| PL4028017T3 (pl) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401544B1 (ar) | [1، 5-a] مركبات بيرازولو بيريدين بها استبدال كمثبطات كيناز معاد ترتيبه أثناء نقل العدوى | |
| SA519401541B1 (ar) | [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| MX2019001900A (es) | Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxife nil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma. | |
| IL279144A (en) | Tetrahydro-1H-pyrazino[2,1-azisoindolylquinoline compounds for the treatment of immune system disease | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| SG10201810660QA (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
| EP3452480A4 (en) | SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
| IL286870A (en) | Hexahydro-h1-pyrazino[a-2,1]pyrazine compounds for the treatment of autoimmune disease | |
| DK3737684T3 (da) | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-on-derivater og relaterede forbindelser som c5a-receptormodulatorer til behandling af vaskulitis og inflammatoriske sygdomme | |
| IL291335A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| IL291338A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| MX2019013198A (es) | Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9). | |
| ZA200809016B (en) | 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders | |
| EP3634963B8 (en) | 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders | |
| PL3634957T3 (pl) | Modulatory receptora NMDA, zawierające je kompozycje oraz zastosowanie tych związków w leczeniu chorób ośrodkowego układu nerwowego | |
| IL291640A (en) | Compounds of 1,8-naphthyridin-2-one for the treatment of autoimmune disease | |
| IL310443A (en) | PYRAZOLO[3,4-B]PYRIDINE compounds for the treatment of autoimmune disease | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
| MX2020007271A (es) | Sales y cristales novedosos. |